NCT02833480View on ClinicalTrials.gov

A Study to Investigate the Differential Effects of Inhaled Symbicort and Advair on Lung Microbiota

PHASE2UnknownINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

January 31, 2021

Study Completion Date

June 30, 2021

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Fluticasone group

DRUG

Budesonide group

DRUG

Formoterol group

Trial Locations (2)

V6Z1Y6

RECRUITING

St. Paul's Hospital, Vancouver

Unknown

RECRUITING

BC Cancer Agency, Vancouver

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

University of British Columbia

OTHER

NCT02833480 - A Study to Investigate the Differential Effects of Inhaled Symbicort and Advair on Lung Microbiota | Biotech Hunter | Biotech Hunter